326 related articles for article (PubMed ID: 10313123)
21. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
22. The Orphan Products Board of the Department of Health & Human Services.
Crooks GM
Prog Clin Biol Res; 1985; 197():19-23. PubMed ID: 4070294
[No Abstract] [Full Text] [Related]
23. The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development.
Engstrom LO
Prog Clin Biol Res; 1985; 197():25-30. PubMed ID: 4070295
[No Abstract] [Full Text] [Related]
24. Creation and development of the public service orphan drug Human Botulism Immune Globulin.
Arnon SS
Pediatrics; 2007 Apr; 119(4):785-9. PubMed ID: 17403850
[TBL] [Abstract][Full Text] [Related]
25. "Creating hope" and other incentives for drug development for children.
Connor E; Cure P
Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
[TBL] [Abstract][Full Text] [Related]
26. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
[TBL] [Abstract][Full Text] [Related]
27. Generic Pharmaceutical Industry Association Orphan Drug Institute.
Haddad W
Prog Clin Biol Res; 1985; 197():41-5. PubMed ID: 4070298
[No Abstract] [Full Text] [Related]
28. The Minor Use and Minor Species Animal Health Act: past, present, and future.
Haley CJ
Food Drug Law J; 2006; 61(1):13-43. PubMed ID: 16838456
[No Abstract] [Full Text] [Related]
29. Rare diseases, orphan drugs, and orphaned patients.
Scheindlin S
Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
[No Abstract] [Full Text] [Related]
30. Orphan drugs and orphan tests in the USA.
Thoene JG
Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190
[No Abstract] [Full Text] [Related]
31. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1984 Jun; 4(3):161-2. PubMed ID: 6096408
[No Abstract] [Full Text] [Related]
32. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
Koivuniemi PJ
Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
[No Abstract] [Full Text] [Related]
33. [Orphan drugs].
Kolár J; Chalabala M; Srámková H
Ceska Slov Farm; 2001 Mar; 50(2):59-65. PubMed ID: 11288591
[TBL] [Abstract][Full Text] [Related]
34. R&D policy, agency costs and innovation in personalized medicine.
Yin W
J Health Econ; 2009 Sep; 28(5):950-62. PubMed ID: 19671480
[TBL] [Abstract][Full Text] [Related]
35. Therapies for inborn errors of metabolism: what has the orphan drug act delivered?
Talele SS; Xu K; Pariser AR; Braun MM; Farag-El-Massah S; Phillips MI; Thompson BH; Coté TR
Pediatrics; 2010 Jul; 126(1):101-6. PubMed ID: 20566615
[TBL] [Abstract][Full Text] [Related]
36. European Medicines Agency support mechanisms fostering orphan drug development.
Butlen-Ducuing F; Rivière F; Aarum S; Llinares-Garcia J
Drug News Perspect; 2010; 23(1):71-81. PubMed ID: 20155221
[TBL] [Abstract][Full Text] [Related]
37. View from the Nation's Capital: the Orphan Drug Act--prospects and problems.
Romansky MA
J Clin Psychopharmacol; 1984 Aug; 4(4):230-2. PubMed ID: 6470200
[No Abstract] [Full Text] [Related]
38. Academic center approaches to orphan drug research and development.
Hauck FP; Chung EY; Van Woert MH
Prog Clin Biol Res; 1985; 197():115-22. PubMed ID: 4070286
[No Abstract] [Full Text] [Related]
39. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
Valverde AM; Reed SD; Schulman KA
Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
[TBL] [Abstract][Full Text] [Related]
40. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
